Repositioning Candidate Details
| Candidate ID: | R0094 |
| Source ID: | DB00250 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Dapsone |
| Synonyms: | 1,1'-sulfonylbis(4-aminobenzene); 1,1'-Sulfonylbis[4-aminobenzene]; 4-(4-amino-benzenesulfonyl)-phenylamine; 4-(4-aminophenylsulfonyl)aniline; 4-(4-aminophenylsulfonyl)benzenamine; 4-aminophenyl sulfone; 4,4'-dapsone; 4,4'-diaminodiphenyl sulfone; 4,4'-Diaminodiphenyl sulphone; 4,4'-Diaminodiphenylsulfone; 4,4'-sulfonylbisaniline; 4,4'-Sulfonylbisbenzenamine; 4,4'-Sulfonylbisbenzeneamine; 4,4'-Sulfonyldianilin; 4,4'-sulfonyldianiline; bis(4-aminophenyl)sulfone; Bis(p-aminophenyl) sulfone; DADPS; Dapsone; DDS; Diaphenylsulfone; p-aminophenyl sulfone; p,p-sulphonylbisbenzamine; p,p-sulphonylbisbenzenamine; p,p'-diaminodiphenyl sulfone |
| Molecular Formula: | C12H12N2O2S |
| SMILES: | NC1=CC=C(C=C1)S(=O)(=O)C1=CC=C(N)C=C1 |
| Structure: |
|
| DrugBank Description: | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8) |
| CAS Number: | 80-08-0 |
| Molecular Weight: | 248.301 |
| DrugBank Indication: | For the treatment and management of leprosy and dermatitis herpetiformis. |
| DrugBank Pharmacology: | Dapsone is a sulfone with anti-inflammatory immunosuppressive properties as well as antibacterial and antibiotic properties. Dapsone is the principal drug in a multidrug regimen recommended by the World Health Organization for the treatment of leprosy. As an anti-infective agent, it is also used for treating malaria and, recently, for Pneumocystic carinii pneumonia in AIDS patients. Dapsone is absorbed rapidly and nearly completely from the gastrointestinal tract. Dapsone is distributed throughout total body water and is present in all tissues. However, it tends to be retained in skin and muscle and especially in the liver and kidney: traces of the drug are present in these organs up to 3 weeks after therapy cessation. |
| DrugBank MoA: | Dapsone acts against bacteria and protozoa in the same way as sulphonamides, that is by inhibiting the synthesis of dihydrofolic acid through competition with para-amino-benzoate for the active site of dihydropteroate synthetase. The anti-inflammatory action of the drug is unrelated to its antibacterial action and is still not fully understood. |
| Targets: | Inactive dihydropteroate synthase 2 inhibitor; Dihydropteroate synthase 1 inhibitor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I01 | 552 | Pneumonia | A lung disease that involves lung parenchyma or alveolar inflammation and abnormal alveolar filling with fluid (consolidation and exudation). It results from a variety of causes including infection with bacteria, viruses, fungi or parasites, and chemical or physical injury to the lungs. It is accompanied by fever, chills, cough, and difficulty in breathing. http://en.wikipedia.org/wiki/Pneumonia | disease of anatomical entity/respiratory system disease/ lower respiratory tract disease/lung disease | Details |